NOVACYT FULL YEAR 2018 RESULTS

Paris, France and Camberley, UK – 30 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its audited financial results for the year ended 31 December 2018 and restated financial results for the year ended 31 December 2017 following the impact of the discontinuing operations of NOVAprep®.

Visit Page

Mise à jour sur la publication des résultats annuels

Paris, France et Camberley, UK – 25 avril 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste international du diagnostic clinique, annonce qu’il prévoit désormais de publier ses résultats audités pour l’exercice clos le 31 décembre 2018, le 30 avril 2019. http://novacyt.com/wp-content/uploads/2019/04/Novacyt-Mise-à-jour-sur-la-publication-des-résultats-annuels.pdf

Visit Page

Update on Notice of Full Year Results

Paris, France and Camberley, UK – 25 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it now intends to report its audited results for the full year ended 31 December 2018, on 30 April 2019. http://novacyt.com/wp-content/uploads/2019/04/Novacyt-update-on-notice-of-FY-results.pdf

Visit Page

Novacyt obtient un financement via des obligations convertibles

Paris, France et Camberley, UK – 23 avril 2019 – Novacyt (EURONEXT GROWTH : ALNOV; AIM: NCYT), spécialiste international du diagnostic clinique se félicite d’annoncer qu’elle a conclu un programme de financement par des Obligations Convertibles assorties de warrants (« l’Accord ») pour un montant maximum de 5,0 millions d’euros (net de dépenses) avec Park

Visit Page

Convertible Bond Facility

Paris, France and Camberley, UK – 23 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that it has entered into a Convertible Bonds with Warrants Funding Programme (“Agreement”), for up to €5.0 million (net of expenses) with Park Partners GP and Negma Group LTD

Visit Page

NOVACYT ÉTEND SON PARTENARIAT DE DÉVELOPPEMENT AVEC IMMUNEXPRESS

Paris, France et Camberley, Royaume-Uni – le 8 avril 2019 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique annonce aujourd’hui que sa division de tests moléculaires, Primerdesign Ltd. (Primerdesign), a étendu son contrat de développement de tests cliniques avec Immunexpress Inc. (Immunexpress), une société américaine spécialisée dans les tests de

Visit Page

NOVACYT EXPANDS DEVELOPMENT PARTNERSHIP WITH IMMUNEXPRESS

Paris, France and Camberley, UK – 8 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has expanded its assay development contract with Immunexpress, Inc. (Immunexpress), a U.S.-based molecular diagnostic company with the first FDA cleared host response test for

Visit Page

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers http://novacyt.com/wp-content/uploads/2019/04/NOVACYT_CP_Droits-de-vote_2019-Apr.pdf

Visit Page

Liquidity Agreement Monthly Update and Total Voting Rights

Paris, France and Camberley, UK – 1 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised

Visit Page

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers http://novacyt.com/wp-content/uploads/2019/03/Contrat-de-liquidité-1-mars-2019.pdf

Visit Page